SURMODICS INC (SRDX) Fundamental Analysis & Valuation

NASDAQ:SRDX • US8688731004

42.98 USD
+0.15 (+0.35%)
At close: Nov 18, 2025
42.99 USD
+0.01 (+0.02%)
After Hours: 11/18/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SRDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall SRDX gets a fundamental rating of 3 out of 10. We evaluated SRDX against 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of SRDX is average, but there are quite some concerns on its profitability. SRDX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. SRDX Profitability Analysis

1.1 Basic Checks

  • SRDX had negative earnings in the past year.
  • In the past year SRDX has reported a negative cash flow from operations.
  • In multiple years SRDX reported negative net income over the last 5 years.
  • SRDX had a positive operating cash flow in 4 of the past 5 years.
SRDX Yearly Net Income VS EBIT VS OCF VS FCFSRDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -10.38%, SRDX is in the better half of the industry, outperforming 61.38% of the companies in the same industry.
  • SRDX's Return On Equity of -15.84% is fine compared to the rest of the industry. SRDX outperforms 63.49% of its industry peers.
Industry RankSector Rank
ROA -10.38%
ROE -15.84%
ROIC N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
SRDX Yearly ROA, ROE, ROICSRDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • SRDX's Gross Margin of 73.09% is amongst the best of the industry. SRDX outperforms 82.54% of its industry peers.
  • In the last couple of years the Gross Margin of SRDX has declined.
  • SRDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
SRDX Yearly Profit, Operating, Gross MarginsSRDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SRDX Health Analysis

2.1 Basic Checks

  • SRDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SRDX has more shares outstanding
  • The number of shares outstanding for SRDX has been increased compared to 5 years ago.
  • SRDX has a worse debt/assets ratio than last year.
SRDX Yearly Shares OutstandingSRDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
SRDX Yearly Total Debt VS Total AssetsSRDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 7.89 indicates that SRDX is not in any danger for bankruptcy at the moment.
  • SRDX has a better Altman-Z score (7.89) than 87.83% of its industry peers.
  • SRDX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of SRDX (0.27) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 7.89
ROIC/WACCN/A
WACC8.75%
SRDX Yearly LT Debt VS Equity VS FCFSRDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • SRDX has a Current Ratio of 3.91. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.91, SRDX is in the better half of the industry, outperforming 67.20% of the companies in the same industry.
  • SRDX has a Quick Ratio of 3.10. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.10, SRDX is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.1
SRDX Yearly Current Assets VS Current LiabilitesSRDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. SRDX Growth Analysis

3.1 Past

  • SRDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -172.73%.
  • SRDX shows a decrease in Revenue. In the last year, the revenue decreased by -0.02%.
  • SRDX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)-172.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.22%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-2.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 42.04% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 1.78% on average over the next years.
EPS Next Y10.36%
EPS Next 2Y18.73%
EPS Next 3Y42.04%
EPS Next 5YN/A
Revenue Next Year-4.48%
Revenue Next 2Y-0.63%
Revenue Next 3Y1.78%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SRDX Yearly Revenue VS EstimatesSRDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
SRDX Yearly EPS VS EstimatesSRDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. SRDX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SRDX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRDX Price Earnings VS Forward Price EarningsSRDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150 -200

4.2 Price Multiples

  • 64.55% of the companies in the same industry are more expensive than SRDX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 86.22
SRDX Per share dataSRDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • SRDX's earnings are expected to grow with 42.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.73%
EPS Next 3Y42.04%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SRDX Dividend Analysis

5.1 Amount

  • No dividends for SRDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SRDX Fundamentals: All Metrics, Ratios and Statistics

SURMODICS INC

NASDAQ:SRDX (11/18/2025, 8:00:01 PM)

After market: 42.99 +0.01 (+0.02%)

42.98

+0.15 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05
Earnings (Next)01-28
Inst Owners77.38%
Inst Owner Change-86.03%
Ins Owners0.01%
Ins Owner Change-260.85%
Market Cap614.61M
Revenue(TTM)120.80M
Net Income(TTM)-17.63M
Analysts45.71
Price Target43.86 (2.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.5%
Min EPS beat(2)-12.46%
Max EPS beat(2)131.46%
EPS beat(4)3
Avg EPS beat(4)60.58%
Min EPS beat(4)-12.46%
Max EPS beat(4)131.46%
EPS beat(8)7
Avg EPS beat(8)83.05%
EPS beat(12)11
Avg EPS beat(12)135.86%
EPS beat(16)15
Avg EPS beat(16)112.5%
Revenue beat(2)1
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)3.32%
Revenue beat(4)2
Avg Revenue beat(4)-4.04%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)7.17%
Revenue beat(8)5
Avg Revenue beat(8)-0.37%
Revenue beat(12)9
Avg Revenue beat(12)3.53%
Revenue beat(16)11
Avg Revenue beat(16)2.67%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.09
P/FCF N/A
P/OCF N/A
P/B 5.52
P/tB 14.17
EV/EBITDA 86.22
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS8.45
BVpS7.78
TBVpS3.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.38%
ROE -15.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.09%
FCFM N/A
ROA(3y)-8.18%
ROA(5y)-4.34%
ROE(3y)-12.06%
ROE(5y)-6.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.3%
GM growth 5Y-3.08%
F-Score2
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA 4.23
Cap/Depr 19.66%
Cap/Sales 1.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.1
Altman-Z 7.89
F-Score2
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)37.09%
Cap/Depr(5y)48.03%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-172.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%122.22%
EPS Next Y10.36%
EPS Next 2Y18.73%
EPS Next 3Y42.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y6.25%
Revenue growth 5Y4.72%
Sales Q2Q%-2.55%
Revenue Next Year-4.48%
Revenue Next 2Y-0.63%
Revenue Next 3Y1.78%
Revenue Next 5YN/A
EBIT growth 1Y68.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200.15%
EBIT Next 3Y61.42%
EBIT Next 5YN/A
FCF growth 1Y-188.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-127.84%
OCF growth 3Y-74.74%
OCF growth 5Y-50.13%

SURMODICS INC / SRDX FAQ

What is the fundamental rating for SRDX stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRDX.


What is the valuation status for SRDX stock?

ChartMill assigns a valuation rating of 1 / 10 to SURMODICS INC (SRDX). This can be considered as Overvalued.


How profitable is SURMODICS INC (SRDX) stock?

SURMODICS INC (SRDX) has a profitability rating of 3 / 10.


Can you provide the financial health for SRDX stock?

The financial health rating of SURMODICS INC (SRDX) is 5 / 10.